Major R&D Pipeline: 3ADCs
Planned Presentation at WCLC/ESMO 2021
WCLC 2021: 9/8-14 (Virtual)
Dato-DXd
TROPION-Pan Tumor01 (Ph1), NSCLC cohort data update
Mini oral presentation
Daiichi-Sankyo
ESMO 2021: 9/16-21 (Virtual)
EnhertuⓇ
Dato-DXd
DS-7300
DESTINY-Lung01 (HER2 mutated/overexpressing, 2L+, Ph2), HER2 mutated cohort data
Late breaking session*
DESTINY-Breast01 (HER2 positive, 3L, Ph2), updated OS data
Poster presentation
TROPION-PanTumor01 (Ph1 NSCLC cohort), sub-analysis of patients with actionable mutations
◆ Late breaking session*
Solid tumor Ph1/2, Ph1 dose escalation data
Oral presentation
NSCLC: non small cell lung cancer, OS: overall survival
* Final decision for the acceptance of late breaking abstract will be made after Aug 17
WCLC/ESMO IR event is planned on Sep 22 morning in JP time
featuring Ken Takeshita Global R&D Head
29
20View entire presentation